Pharmaceuticals, Biotechnology and Life Sciences
− Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over…
First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors B7-H3 is…
SAN DIEGO–(BUSINESS WIRE)–Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today…
15 patients have been randomized 83% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced…
PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc., a leading provider of a digital trial platform connecting patients, sites, and clinical trial teams,…
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced a…
– Strong total revenue of $4.5 billion, increased 16% Y/Y driven by volume – INREBIC® (fedratinib) granted FDA approval in…
– Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…
Accelerated approvals of new biologics will drive market growth in North America LONDON–(BUSINESS WIRE)–#AmgenInc–Technavio’s report on the cancer biologics market…